Salt-sensitive hypertension (SSH), an intermediate inherited phenotype of essential hypertension, 1 has caused wide concern since it was first proposed as an independent condition by Kawasaki in 1978. 2 In a 27-year follow-up study it was found that salt-sensitive subjects were at an increased risk of age-related hypertension, as well as of cardiovascular events and death. 3 So, treatment of SSH is of importance for diminishing the risk of adverse cardiovascular outcomes.
Salt-sensitive hypertension (SSH), an intermediate inherited phenotype of essential hypertension, 1 has caused wide concern since it was first proposed as an independent condition by Kawasaki in 1978. 2 In a 27-year follow-up study it was found that salt-sensitive subjects were at an increased risk of age-related hypertension, as well as of cardiovascular events and death. 3 So, treatment of SSH is of importance for diminishing the risk of adverse cardiovascular outcomes.
Due to SSH differing from salt-resistant hypertension (such as salt retention and an increase in renal vascular resistance in response to high salt intake), treatment of SSH patients would be better targeted and individualized. However, current guidelines do not recommend optimal antihypertensive agents for SSH patients. Evidence-based guidelines (2014) for the management of high blood pressure (BP) in adults recommend that in the non-black population (including those with diabetes) initial antihypertensive treatment should include a thiazide-type diuretic, angiotensin-converting enzyme inhibitor (ACEi), and a calcium channel blocker (CCB) or angiotensin receptor blocker (ARB). However, for the general black population, who have been confirmed to have a higher prevalence of SSH, 4 initial antihypertensive agents should include a thiazide-type diuretic or CCB. 5 In 1 study it was demonstrated that when compared with Lisinopril, Omapatrilat lowered ambulatory BP in patients with SSH. 6 A randomized double-blind study showed that another antihypertensive agent, Nifenipine, reduced BP in groups of hypertensive patients with low salt and high salt diets, and the effect was greater in salt-sensitive subjects with high salt diets. 7 In the light of the optimal Comparative Efficacy of Antihypertensive Agents in Salt-Sensitive Hypertensive Patients: A Network Meta-Analysis Han Qi, 1,# Zheng Liu, 1,# Han Cao, 1 Wei-Ping Sun, 1, 2 Wen-Juan Peng, 1 Bin Liu, 1 Sheng-Jie Dong, 3 Yu-Tao Xiang, 4 and Ling Zhang 1 BACKGROUND Salt-sensitive hypertension (SSH) is an intermediate inherited phenotype of essential hypertension as well as being an independent risk factor for cardiovascular disease. However, effective medications for the treatment of SSH have not been clarified. This study was to compare the efficacious of different classes of antihypertensive agents combined with salt intake on the reduction of blood pressure (BP) in patients with SSH.
METHODS
We used sources as PubMed, EMBASE, Cochrane Library, Cochrane Central Register of Controlled Trials (CENTRAL), ClinicalTrials.gov, International Clinical Trials Registry Platform (ICTRP), CNKI, and WANFANG database from inception to November 2016. Studies that compared the efficacy of 2 or more antihypertensive agents or placebos in adult salt-sensitive hypertensive patients were included. The outcomes included variations in mean arterial blood pressure, systolic and diastolic blood pressure.
RESULTS
Twenty-five studies were involved in this meta-analysis. A calcium channel blocker (CCB) with hydrochlorothiazide and moderate salt intake was significantly the most efficacious in comparison with placebo (standardized mean differences (SMD), 95% credibility intervals (CI): 26 choice for treatment being controversial and the lack of evidence from systematic reviews and meta-analysis, network meta-analysis (NMA) was performed to directly or indirectly compare SSH treatments and to rank them. 8 A meta-analysis demonstrated that, in white participants with hypertension, sodium reduction, from an average high sodium intake of 201 mmol/day to an average low of 66 mmol/ day, resulted in a decrease in systolic blood pressure/diastolic blood pressure (SBP/DBP) of 5.5/2.9 mm Hg. Some studies have also shown that these effects in black and Asian populations are greater. 9 Therefore, it appears that different levels of salt intake influence the effects of antihypertensive agents. It is more clinically relevant to analyze the efficacy of antihypertensive agents when these are combined with the level of salt intake, which will not only offer a guide to a healthier lifestyle, but achieve the best antihypertensive effects. In the current study, we compared the effectiveness of different classes of antihypertensive agents combined with salt intake levels on the reduction of BP for SSH patients by using a NMA.
METHODS
The protocol for the current NMA was registered in the international prospective register of systematic reviews (PROSPERO) on November 2016, and is available from https://www.crd.york.ac.uk/PROSPERO with the registration number CRD42016052913.
Eligibility criteria
We included the trials that compared any of the 5 classes of antihypertensive agents including ACEi, ARB, CCB, beta blockers (β-blockers), thiazides and combination therapies in the treatment of adults with SSH for meta-analysis. The primary endpoints were changes in mean arterial blood pressure (MABP), as well as in SBP and DBP. The incidence of cardiovascular events and side effects were secondary outcomes. Randomized controlled trials (RCTs), non-RCTs, and self-controlled trials could be included in the meta-analysis in any language.
Search and study selection
The following electronic databases were systematically searched from inception to November 2016: PubMed, EMBASE, the Cochrane Library, CNKI, WANFANG, Cochrane Central Register of Controlled Trials (CENTRAL), ClinicalTrials.gov, and the International Clinical Trials Registry Platform (ICTRP) using the Medical Subject Heading terms "essential hypertension, " the defined name of each drug, and "salt sensitive. " Studies comparing the efficacy of 2 or more antihypertensive drugs, or placebos, on adult SSH patients were included. The follow-up period was unlimited (the detailed search strategy is described in the Supplementary Material). Two reviewers (H.Q. and Z.L.) independently selected the studies after reading the title and abstract, and assessing the completeness of data abstraction. The potentially eligible studies were retrieved with the full text in order to acquire detailed information. If there was no consensus, a third reviewer (H.C.) was consulted.
Data extraction and quality assessment
The following data were extracted from the eligible studies into a structured data abstraction form by reviewers (H.Q., Z.L., and H.C.): author, country, publication year, duration of follow-up, sample size, salt intake, body mass index, mean age, ethnicity, classes of the antihypertensive agent used, SSH diagnostic method, as well as changes in SBP, DBP, or MABP. Two reviewers independently evaluated the risk of bias (ROB), according to the Cochrane collaboration's tool for assessing the ROB for RCT (http://handbook. cochrane.org/chapter_8/table_8_5_a_the_cochrane_collab-orations_tool_for_assessing.htm), and the Cochrane Risk of Bias Assessment Tool for Non-Randomized Studies of Interventions (ACROBAT-NRSI). 10 
Data and statistical analysis
As differences in MABP before and after antihypertensive agents were continuous variables, results were expressed as mean ± SD. If only SBP and DBP were given in studies, MABP was calculated using the following equation:
A correlation coefficient, Corr 0.5, was used to calculate the SD for changes from baselines and to synthesize this with covariance formula derivation. 11 Salt intake was divided into low salt intake (LS), moderate salt intake (MS), and high salt intake (HS). According to the design of the original studies, comparisons were divided into 2 situations: (i) comparison of the effects of 1 drug between different levels of salt intake (e.g., CCBLS vs. CCBMS); (ii) comparison of the effects of 2 or 3 drugs with the same level of salt intake (e.g., CCB/ MS vs. ACEi/MS). We combined these 2 situations by seeing each drug with a different salt intake level as a new intervention (e.g., CCB/LS represents CCB under low salt intake, CCB/MS represents CCB under moderate salt intake. CCB/ LS and CCB/MS are 2 different interventions).
We performed a random effects model within a Bayesian framework using Markov chain Monte Carlo methods in WinBUGS (MRC Biostatistics Unit, Cambridge, UK). 12 We modeled the mean difference in the BP outcome and reported posterior mean differences with 95% credibility intervals (CIs). Each chain used 10,000 iterations with a burn-in number of 1,000, and a thin interval of 1. The code is available in the Supplementary Material. Deviance information criteria were performed to evaluate statistical heterogeneity between fixed and random effects models. 13 Inconsistency between direct and indirect evidence was evaluated using the node-split method. 14 The surface under the cumulative ranking curve (SUCRA) was used to compare the different antihypertensive classes, and the larger value of SUCRA implied a high ranking. 15 We performed metaregression and subgroup analysis to elucidate the sources of heterogeneity using Stata 13.0 software (StataCorp, College Station, TX). Sample size, countries, diagnostic method used for SSH, and salt intake were considered when conducting meta-regression. Body mass index, salt intake, and the diagnostic method used for SSH were used to conduct subgroup analyses with inverse-variance weighting methods. Finally, publication bias was assessed for the outcomes using funnel plots, Egger's test, and trim and fill method. Stata software was also used to create images of the data.
RESULTS

Study selection
The search retrieved 200 studies, 62 of which were removed after duplication. Then, 30 studies were excluded based on their titles and abstracts. The remaining 108 studies were assessed for full text analysis, but 85 were excluded as they failed to meet the inclusion criteria. Finally, there were 23 studies and 1,935 individuals included in the following analyses comparing the effects of different antihypertensive treatments on SSH ( Figure 1 ). Two of the 23 studies compared 2 or 3 classes of antihypertensive agent with 2 levels of salt intake, so we separated the trials according to salt intake levels and then viewed them as different interventions (e.g., 1 trial compared CCB and ACEi with LS and HS. The trial was separated into 2 studies with CCB/LS vs. ACEi/LS, and CCB/HS vs. ACEi/HS), so that the final number of studies included was 25.
Characteristics of the studies
In Table 1 , detailed information about the 25 studies included in the current analysis is summarized. Among the 25 studies 6, 7, that contributed to this analysis, 5 main types of antihypertensive interventions were involved: 8 studies for CCB, 3 studies for ACEi, 4 studies for CCB with ACEi, 1 study for ARB, 1 study for ARB with ACEi and 8 studies for combination treatments as well as interventions not belongs to the 5 types. The study sample size ranged from 12 to 397. The studies were published between 1987 and 2016, none of which mentioned the incidence of cardiovascular events and only one of them mentioned side effects; it is not possible for us to describe these in the results. The mean low salt intake was 3.26 g/day (55.69 mmol sodium), high salt intake was 13.40 g/day (228.98 mmol sodium), and moderate salt intake was 7.02 g/day (120 mmol sodium), values that were calculated from those reported in the original studies.
Quality of the studies included
The ROB in the studies included here is described in Supplementary Figure S1 and Supplementary Tables S1 and S2. Nineteen studies with randomized allocation were assessed by ROB. Another 6, in which the method used for randomization could not be defined, were assessed by ACROBAT-NRSI. For the ROB results, all 19 studies were unclear in terms of allocation concealment. Eight studies were double-blinded and 3 were blinded in terms of outcome assessment. For incomplete outcome assessments, 15 studies had a low risk, and in another 4 studies the risk could not be defined. In 18 studies, selective reporting bias was of low risk, except in one. All of the studies had a low risk in other bias domains (e.g., funding, study's early discontinuation, Figure 1 . Flow diagram of the study selection. Two studies of the 23 studies had different data extracted twice so the final study number was 25. and baseline imbalances). For non-RCT studies, 3 had a low ROB due to confounding, and the other had a serious risk. All 6 studies had a low ROB in terms of the selection of participants into the study, bias due to departures from intended interventions, and selection of the reported results. However, in terms of the bias in the measurement of interventions as well as outcomes, all 6 studies were of moderate risk. Five studies had a low ROB due to missing data. A funnel plot demonstrated that there were few publication biases observed using such a graphical analysis.
Changes in MABP before and after medication
In studies reporting the effects of antihypertensive agents vs. placebos on changes in MABP between follow-up and baseline, the MABP change of traditional meta-analysis was −4.74 ± 1.95 for CCB with LS, −5.90 ± 5.15 for CCB with MS, −9.83 ± 2.13 for CCB with HS, −13.63 ± 6.44 for CCB combined with metformin in LS, −22.37 ± 9.66 for CCB combined with metformin in MS, −17. As the deviance information criteria of the random effects model was similar to that of the fixed effects model, 353.863 and 352.870, respectively, we used the more conservative random effects model to construct the NMA. The pairwise meta-analyses of MABP changes from the baseline were significantly reduced following antihypertensive therapy (standardized mean differences (SMD), 95% CI: −1.67, −1.79 to −1.55 with the random effects model, I 2 = 97.6%, P < 0.001) (Figure 2) . Figure 3 illustrates the network of direct comparisons for SSH interventions. Fifteen interventions combining antihypertensive drugs and salt intake were included. We also performed a random effects NMA model, which combined direct and indirect evidence in order to compare different antihypertensive drugs. For hypertensive patients without other diseases, clonidine with LS intake resulted in an overall higher MABP reduction in comparison to the other 14 interventions (Table 2 ). CCB combined with hydrochlorothiazide and MS intake also had a better efficacy for the lowering of MABP in comparison to placebo (SMD, 95% CI: 18.61, 9.31 to 21.33), CCB alone (SMD, 95% CI: 13.69, 3.51 to 23.64), and ARBs (SMD, 95% CI: 14.89, 0.7 to 29.57). ARBs taken with HS intake were inferior in efficacy to 13 other interventions, except for a placebo treatment (SMD, 95% CI: 3.57, −7.75 to 14.85). For patients with obesity, CCB combined with metformin in the normal diet was superior to CCB (SMD, 95% CI: 17.90, 6.26 to 29.33) and other interventions ( Table 2) .
The ranking of treatments was performed using a SUCRA plot (Figure 4) . Clonidine/LS (93.6%) followed by CCBME/ MS (87.9%) represented the best cumulative probabilities of being the best treatment. In Table 3 , direct effect size came from traditional pooled analysis and indirect effect size came from network analysis which based on Bayesian theory using Abbreviations: BMI, body mass index; RCT, randomized controlled trial; SS, salt-sensitivity of blood pressure; MABP, mean arterial blood pressure; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker II; CCB, calcium channel blocker; Hy, hydrochlorothiazide; ME, metformin; LS, low salt intake; MS, moderate salt intake; HS, high salt intake; SSH, salt-sensitive hypertension. Table 1 .
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WinBUGS software. Node-splitting analysis of inconsistencies resulted in no significant (P > 0.05) discrepancies between direct and indirect estimates for most interventions, except for CCB in HS vs. placebo (P = 0.03).
Publication bias, meta-regression, subgroup analysis, and sensitivity analysis
Graphical assessments with funnel plots showed studies scattered symmetrically on the both sides of the vertical line (Supplementary Figure S2) . The trim and fill method did not reveal publication bias because no trimming performed and data unchanged. However, the Egger's test suggests publication bias (P = 0.028). In order to find the potential sources, the Egger's test was conducted in each subgroup (Supplementary  Table S3 ). Finally, publication bias existed in studies with low salt intake (P = 0.035) and normal weight (P = 0.020) and those reported in Portugal (P = 0.016). Countries, diagnostic method of SSH, and sample size were regarded as covariables for meta-regression. Each variable was assigned with dummy variables according to the classification. The results showed that the diagnostic methods of SSH and sample size were not associated with differences in outcomes in terms of administering different antihypertensive agents (P > 0.05). Network of direct comparisons for the antihypertensive agents combined with salt intake for salt-sensitive hypertension. The size of the node and the width of the lines are proportional to the number of trials. The gray scale of the line represents the bias risk of randomization, black was low risk and gray was unclear. Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker II; CCB, calcium channel blocker; Hy, hydrochlorothiazide; ME, metformin; LS, low salt intake; MS, moderate salt intake; HS, high salt intake. However, only country was associated with differences in outcome and this was significant (P < 0.05; Supplementary Table S4) . We also undertook a sensitivity analysis to explore whether our conclusion was robust or arbitrary. The result showed most studies did not change the trend of result, and there were no changes of result when trim and fill method was conducted. So our decision was convinced and robust (Supplementary Figure S8) . Further subgroup analyses showed that salt intake level of HS decreased BP effectively (SMD = −2.86, 95% CI: −4.02 to −1.70). For the different diagnostic method of SSH (chronic salt loaded, Sullivan, intravenous injection and not clear), chronic salt loaded performed best than the other 2 methods (SMD = −2.99, 95% CI: −3.17 to −2.81). We also performed subgroup analysis stratified by body mass index (obesity or normal weight) and study type (RCT or non-RCT). Obesity participants seemingly had better antihypertensive effectiveness than normal weight (SMD = −1.88, 95% CI: −2.17 to −1.59). Similarly, the results of RCT studies were better than non-randomized studies (SMD = −1.76, 95% CI: −1.89 to −1.62). Studies that reported by Brazil had the best antihypertensive effectiveness than other countries. However, all subgroups displayed substantial heterogeneity between studies (Supplementary Table S3 and Supplementary Figures S3-S7 ).
DISCUSSION
The salt sensitivity of blood pressure is a risk factor for cardiovascular mortality and morbidity independently of BP. 3 Hence, treatment of salt sensitivity of blood pressure needs to be addressed as a risk factor in its own right, apart from BP treatments, once the underlying mechanisms are elucidated and appropriate therapies devised. 37 However, due to the fact that the diagnostic methods for assessing salt sensitivity of blood pressure patients involve complex procedures, few original studies that have compared different medications for SSH and the sample size is usually small. So, we aimed to systematically search all drug curative evaluation researches in adult salt-sensitive hypertensive patients, and compare the efficacy of 2 or more antihypertensive drugs including which have yet been compared directly by a NMA so far. This is the first systematic investigation using NMA methodology for comparing the effects of 5 classes of antihypertensive drugs on BP reduction in patients with SSH. Twenty-five studies and 15 interventions were included. The levels of salt intake were considered to determine the optimal medication due to the effect of sodium on BP.
The results presented suggest that the generally most effective intervention for SSH was CCB combined with The surface under the cumulative ranking curve (SUCRA) for the 15 interventions. Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker II; CCB, calcium channel blocker; Hy, hydrochlorothiazide; ME, metformin; LS, low salt intake; MS, moderate salt intake; HS, high salt intake.
hydrochlorothiazide in MS intake. This finding is consistent with the recommendation of "Eight Joint National Committee (JNC 8)" for the black hypertensive population. 5 The prevalence of salt sensitivity in African Americans has been determined to be higher than in Caucasians. The causes of such racial disparities may be due to renal damage. A chronic increase in glomerular capillary hydraulic pressure finally causes renal damage in African Americans who habitually consume high levels of salt. 4 Similarly, higher renal vascular resistance and lower renal blood flow were found to be the important factors influencing salt sensitivity in essential hypertension. 38, 39 Also, long-term high sodium intake could enhance the secretion of a circulating inhibitor of Na + /K + -ATPase, which increases the intracellular concentration of Na + , and augments intracellular Ca 2+ concentrations by disturbing Na + /Ca 2+ exchange. 40 CCBs are a group of medications that disrupt L-type voltage-dependent calcium channels and act mainly directly on vasodilation in vascular smooth muscle, with a resultant decrease in vascular resistance. 41 CCBs and thiazide-type diuretics such as hydrochlorothiazide have antihypertensive effects due to the inhibition of the sodium-chloride symporter and also have a vasodilatory effect. A combination of CCB and hydrochlorothiazide target the pathogenic mechanism of SSH and could be the optimal choice for decreasing the unhealthy BP rise.
Our result detected that the benefits of the reduction of MABP were greater in clonidine group than ACEi, ARBs, or placebo groups in low salt intake patients. Clonidine is a central α 2 -adrenergic agonist. Some research have reported that initial treatment with an diuretic had the advantages of superior BP control, greater tolerability, and a significant reduction in cardiovascular events, 42 and so it is confirmed the superiority of diuretic-based over α-blocker-based for the prevention of CVD.
For moderate salt intake, obese SSH patients, CCB combined with metformin seemed to produce the greatest reduction in BP. Insulin resistance is one of the defining clinical features in the obesity, 43 which also involved in the mechanism of SSH through the role of hyperinsulinemia, sympathetic nervous system over-activation, and a reduction in the suppression of the RAS pathway. 44 Metformin, the firstline medication for type 2 diabetes, works by decreasing liver glucose production and increasing insulin sensitivity of body tissues, particularly in people who are overweight. 45 It could also improve salt sensitivity and reduce the BP of SSH patients with concomitant obesity. This combination treatment was specific for hypertensive patients with obesity and could be a supplement to the treatment of hypertension.
Other relevant meta-analyses have involved evaluating the effects of monotherapies with thiazide diuretics 5 or CCB 46 for hypertension. CCB increased the total cardiovascular events compared to diuretics, so diuretics became the preferred first-line treatment over CCB. 46 However, in that study, the reduction of BP with CCB and diuretics or a combination of them was not investigated. Besides, the subjects of these meta-analyses were general hypertensive patients, these recommendations could not be used for SSH patients directly. Thus, it is necessary to compare the reduction of BP of CCB and diuretics or a combination of them for SSH patients.
This NMA makes comparisons of both direct and indirect evidence in SSH patients, and environmental factors such as salt intake level were taken into consideration. In the 25 studies, 7 studies had compared one kind of antihypertensive agents with 2 levels of salt intake (low salt vs. high salt). We discovered that the effectiveness of antihypertensive agents was better in high salt level than in low salt levels. The main biological pathways involved in SSH are reported to be the renin-angiotensin-aldosterone system (RAAS), Abbreviations: ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker II; CCB, calcium channel blocker; Hy, hydrochlorothiazide; ME, metformin; LS, low salt intake; MS, moderate salt intake; HS, high salt intake.
the endothelial system, ion and water channels, intracellular messengers, the sympathetic nervous system, the Apelin-APJ system, and the natriuretic peptide system. 47 High salt intake would increase the retention of salt and thereby increased BP. The antihypertensive effectiveness produced by agents such as diuretic could act on RAAS or ion-water channels and accelerate the excretion of salt and thereby decrease BP immensely. The same phenomenon was observed in CCB and ACEI. The contributions of RAAS, renal sympathetic nerve activity, and linked cellular transport of calcium may explain the effect of CCB on high salt intake. In the 5 studies that compared 1 or 2 antihypertensive agents in low salt intake, variety changes of MAP were observed. The antihypertensive effectiveness of CCB and ACEi were greater than placebo. However, the comparison between different antihypertensive agents was influenced by dosage and form of agents, variety of samples as well as the design of studies, which may also result in heterogeneity. Similarly, in moderate and high salt intake, different kinds of antihypertensive agents performed different efficacy for salt-sensitive hypertensive patients.
However, salt restriction has been the first choice for the nondrug treatment of hypertension. It has been shown that reducing salt intake to below 100 mmol/day could substantially lower BP. 48 Similarly, in the Dietary Guidelines for Chinese Residents (2016), the daily recommended salt intake for adults is no more than 6 g. 49 In hypertensive patients already on drug therapy, a reduced salt intake can further lower BP, especially in blacks. 50 The reason we considered the salt dosage in which the original studies were conducted was to come up with a recommendation for the optimal collocation of medicine and diet, and ultimately to achieve the goal of BP control.
Our results found the optimal therapy for different populations are difference. For normal body weight hypertension patients CCB combined with hydrochlorothiazide in MS is best, while for obese hypertension patients CCB combined with metformin in MS is better. As hypertension-related mechanisms differ among subgroups of patients, the effectiveness of antihypertensive agents vary among individual patients, which is consistent with the idea of precision medicine. 51 In comparison to traditional evidence-based medicine, precision medicine highlights the importance of a new taxonomy of disease with an "Information Commons" and "Knowledge Network" using multiomics data. There are great potential opportunities and challenges for using these data to improve health outcomes. 52 The recommendations that we make need to use the opportunities of precision medicine, seeking biomarkers as drug targets to integrate basic biological knowledge with doctors' experiences, and translating these into clinical medicine and individualized medication.
Limitations
The findings should be explained with caution due to some methodological limitations. First, some important outcomes, such as side effects, were not included in this analysis since most original publications have not shown the relevant data. Second, we did not perform subgroup analyses by the dosage of medicines used and the duration of follow-up, because we compared the effectiveness of 5 classes of antihypertensive agents including ACEi, ARB, CCB, beta blockers (β-blockers), thiazides, instead of monotherapy. In addition, most of the studies included were single-center studies without any specific description of randomization and blinding. Third, most relevant studies were based on case-control or self-control design in literature search. In order to increase the power of this meta-analysis, we included both RCTs and controlled clinical trials although unclear risk of allocation concealment and blinding of outcome usually exist in controlled clinical trials. Fourth, the Egger's test revealed publication bias existed in studies with low salt intake and normal weight and those reported in Portugal, although both published and some unpublished studies (i.e., clinical registry platform, such as CENTRAL and ICTRP, academic dissertation, and conference abstract) were included in literature search. The publication bias is probably due to the relatively small number of studies in certain subgroups and the fact that some studies without significant results were less likely to get published. Finally, some studies with relatively small sample size might bias the accuracy of the findings to uncertain extent.
CONCLUSIONS
The present NMA suggested that CCB combined with diuretics are the most effective drugs in reducing BP for adult SSH patients. The optimal therapy for different subgroups is difference. For obese SSH patients, CCB combined with metformin appeared to have the highest degree of efficacy in reducing BP.
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